Abstract
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to <6 years when administered as a primary series in sars-cov-2 vaccine-nave participants part 1 and a single booster dose given to participants who previously received 2 doses of the mrna-1273 vaccine as a primary series part 2.>
